Global Pharmaceuticals, the generics division of Impax, commenced product shipment, as part of a distribution, license, development and supply agreement with AstraZeneca UK.
Zomig is indicated to treat migraine headaches in adults.
Zomig and Zomig-ZMT are registered trademarks of the AstraZeneca group of companies.
The sales of Zomig tablets and orally disintegrating tablets in the 12 months ended April 2013 in the US were approximately $196m, according to IMS Health data.